Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Prothena Corp (PRTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 542,621
  • Shares Outstanding, K 39,840
  • Annual Sales, $ 27,520 K
  • Annual Income, $ -153,240 K
  • 36-Month Beta 2.88
  • Price/Sales 19.72
  • Price/Cash Flow N/A
  • Price/Book 1.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.05
  • Number of Estimates 3
  • High Estimate -0.99
  • Low Estimate -1.12
  • Prior Year -1.37
  • Growth Rate Est. (year over year) +23.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.23 +9.08%
on 09/18/18
15.91 -16.15%
on 09/04/18
-2.17 (-13.99%)
since 08/21/18
3-Month
12.23 +9.08%
on 09/18/18
15.91 -16.15%
on 09/04/18
-1.70 (-11.30%)
since 06/21/18
52-Week
10.43 +27.90%
on 04/25/18
70.00 -80.94%
on 09/28/17
-51.71 (-79.49%)
since 09/21/17

Most Recent Stories

More News
September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc(PRTA)

National securities litigation law firm Glancy Prongay & Murray LLP ("GPM")reminds investors of theSeptember 17, 2018 deadline to file a lead plaintiff motion in the class action filed...

PRTA : 13.34 (-2.06%)
September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

National securities litigation law firm Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors...

PRTA : 13.34 (-2.06%)
Why Is Prothena (PRTA) Up 8.2% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PRTA : 13.34 (-2.06%)
EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc - PRTA

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Prothena Corporation plc (NASDAQ: PRTA) from...

PRTA : 13.34 (-2.06%)
Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)

National securities litigation law firm Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired the securities...

PRTA : 13.34 (-2.06%)
The Law Offices of Howard G. Smith Reminds Investors of Extended Lead Plaintiff Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)

Law Offices of Howard G. Smithreminds investors of the September 17, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Prothena...

PRTA : 13.34 (-2.06%)
Is Celgene Set to See Improved Results in the Second Half?

After a series of pipeline setbacks, things are looking better for biotech bigwig Celgene (CELG) with positive data read-outs and an increase in guidance.

CELG : 87.72 (-0.66%)
BLUE : 140.35 (-1.09%)
XLRN : 56.66 (-3.10%)
PRTA : 13.34 (-2.06%)
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus

Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.

CELG : 87.72 (-0.66%)
PRTA : 13.34 (-2.06%)
GILD : 75.51 (+0.91%)
RHHBY : 30.6200 (+0.07%)
Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -11.36% and 29.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

PRTA : 13.34 (-2.06%)
Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update

- Net loss was $59.9 million in the second quarter and $108.6 million for the first six months ended June 30, 2018

PRTA : 13.34 (-2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade PRTA with:

Business Summary

Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson's disease, MCAM for Inflammatory disease and...

See More

Key Turning Points

2nd Resistance Point 13.99
1st Resistance Point 13.66
Last Price 13.34
1st Support Level 13.13
2nd Support Level 12.93

See More

52-Week High 70.00
Fibonacci 61.8% 47.24
Fibonacci 50% 40.22
Fibonacci 38.2% 33.19
Last Price 13.34
52-Week Low 10.43

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar